Education
About Us
Working with TipRanks
Follow Us
PPH - ETF AI Analysis
Top Page
VanEck Pharmaceutical ETF (PPH)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains over the last three months, indicating positive recent momentum.
Leading Pharma Holdings
Several major pharmaceutical companies in the top holdings have delivered steady to strong year-to-date results, supporting the fund’s overall performance.
Focused Healthcare Exposure
Concentrating on the health care sector allows investors to target a defensive, essential industry that can be more resilient across market cycles.
Negative Factors
High Stock Concentration
A large portion of the fund is invested in just a few companies, which increases the impact if any of those stocks run into trouble.
Sector Concentration Risk
Almost all assets are in the health care sector, so the ETF could be hit hard if pharmaceuticals or health care stocks fall out of favor.
Mixed Performance Among Top Holdings
A couple of the larger positions have shown weak year-to-date performance, which can drag on the fund even when other holdings are doing well.
PPH vs. SPDR S&P 500 ETF (SPY)
AUM1.28B
RegionGlobal
Expense Ratio0.36%
Beta0.46
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield1.73%
Asset ClassEquity
Index TrackedMVIS US Listed Pharmaceutical 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume354,038
30 Day Avg. Volume426,668
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
120.14Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PPH Summary
The VanEck Pharmaceutical ETF (PPH) is a fund that follows the MVIS US Listed Pharmaceutical 25 Index, focusing on large drug and medicine makers. It holds big, well-known companies like Eli Lilly and Pfizer, which develop and sell treatments for many health conditions. Someone might invest in PPH to get simple, diversified exposure to the global pharmaceutical industry, which can benefit from aging populations and rising healthcare spending. However, this ETF is heavily focused on drug companies, so its value can swing with changes in drug pricing, regulation, and healthcare news.
How much will it cost me?The VanEck Pharmaceutical ETF (PPH) has an expense ratio of 0.36%, which means you’ll pay $3.60 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a specialized sector, the pharmaceutical industry, which may require more research and management to track effectively.
What would affect this ETF?The VanEck Pharmaceutical ETF (PPH) could benefit from trends like aging populations, increased healthcare spending, and advancements in medical research, which drive demand for innovative treatments and medications. However, it may face challenges from regulatory changes, patent expirations, or pricing pressures in the pharmaceutical industry, which could impact the profitability of its top holdings like Eli Lilly, Novartis, and Pfizer.
PPH Top 10 Holdings
PPH is a pure play on Big Pharma, with nearly all its firepower in global drugmakers rather than broader health care. Eli Lilly is the fund’s heavyweight, but its recent slide means it’s no longer doing the heavy lifting. Instead, rising names like Novartis, Merck, GSK, and AstraZeneca are pulling most of the load, helped by steady contributions from Johnson & Johnson and Pfizer. With a mix of U.S. and European giants, the ETF is concentrated by sector but diversified across regions and pipelines.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 18.50% | $235.85M | $934.24B | 13.89% | 72 Outperform | |
| Novartis | 11.41% | $145.41M | $302.10B | 38.55% | 80 Outperform | |
| Merck & Company | 9.55% | $121.68M | $286.28B | 22.33% | 80 Outperform | |
| Bristol-Myers Squibb | 4.99% | $63.60M | $122.78B | -1.31% | 78 Outperform | |
| Johnson & Johnson | 4.88% | $62.22M | $579.34B | 44.22% | 78 Outperform | |
| Pfizer | 4.83% | $61.50M | $153.81B | 1.20% | 74 Outperform | |
| McKesson | 4.82% | $61.43M | $112.60B | 42.69% | 62 Neutral | |
| Novo Nordisk | 4.82% | $61.40M | $171.30B | -55.74% | 73 Outperform | |
| GlaxoSmithKline | 4.80% | $61.22M | $109.49B | 36.10% | 77 Outperform | |
| AstraZeneca | 4.52% | $57.65M | $301.48B | 20.11% | 80 Outperform |
PPH Technical Analysis
Negative
―
Price Trends
107.28
Negative
102.04
Positive
94.75
Positive
Market Momentum
0.15
Positive
39.18
Neutral
24.56
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PPH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 109.95, equal to the 50-day MA of 107.28, and equal to the 200-day MA of 94.75, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 39.18 is Neutral, neither overbought nor oversold. The STOCH value of 24.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPH.
PPH Peer Comparison
Comparison Results
Performance Comparison
PPH
VanEck Pharmaceutical ETF
105.94
14.11
15.37%
CIBR
First Trust NASDAQ Cybersecurity ETF
―
―
―
BAI
iShares A.I. Innovation and Tech Active ETF
―
―
―
GRID
First Trust Nasdaq Clean Edge Smart GRID Infrastructure Index
―
―
―
SHLD
Global X Defense Tech ETF
―
―
―
IXJ
iShares Global Healthcare ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents